1. Long-term treatment with upadacitinib resulted in sustained remission for many patients with moderate to severe ulcerative colitis.
2. The study demonstrated high remission rates, including for patients with prior biologic treatment failure.
3. Endoscopic remission was defined as the absence of visible inflammation during colonoscopy and was achieved by nearly half of the participants by week 96.
4. Many patients achieved corticosteroid-free remission by week 96, with 69% discontinuing corticosteroids while maintaining clinical remission.
5. Safety assessment revealed commonly reported adverse events and infrequent serious adverse events.
6. Three deaths were reported during the study period.
7. This study sheds light on the long-term safety and efficacy of upadacitinib in patients with ulcerative colitis.

Source: The Lancet Gastroenterology & Hepatology